Capital Flow Monitor · Sponsors · CIK 2116676
Everest Biolabs, Inc.
204 SECOND AVE, WALTHAM, MA, 02451 · 6172140840
Biotechnology · Corporation· inc. DELAWARE true 2024
Fit score
—
Offering
$5.7M
Sold
$4.4M
% sold
77.0%
Investors
7
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-03-11 | D ·current | 506(b) | $5.7M | $4.4M | 77.0% | 7 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- George Daaboul — Executive Officer / Director, Waltham, MA
- David Freedman — Executive Officer / Director, Waltham, MA
-
David Walt — Director, Waltham, MA
1 other raise
- Vizgen, Inc. $47.8M of $50.0M · 95.6%
-
Paul Meister — Director, Waltham, MA
5 other raises
- Way Biosolutions, Inc. $2.0M of $2.0M · 100.0%
- GCM Grosvenor Credit Secondaries Structured Note 2025, L.P. $625.0M of —
- GCM Grosvenor Credit Secondaries Structured Note 2025 Feeder, L.P. $10.4M of —
- Flywheel Exchange Inc. $16.4M of $27.4M · 59.7%
- BlueWhale Bio, Inc. $5.0M of $15.0M · 33.3%
- Vinit Nijhawan — Director, Waltham, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.